West Pharmaceutical Services EBITDA 2012-2026 | WST
West Pharmaceutical Services annual and quarterly EBITDA history from 2012 to 2026. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- West Pharmaceutical Services EBITDA for the quarter ending June 30, 2026 was $0.225B, a 15.48% increase year-over-year.
- West Pharmaceutical Services EBITDA for the twelve months ending June 30, 2026 was $0.862B, a 15.85% increase year-over-year.
- West Pharmaceutical Services 2025 annual EBITDA was $0.756B, a 4.27% increase from 2024.
- West Pharmaceutical Services 2024 annual EBITDA was $0.725B, a 10.82% decline from 2023.
- West Pharmaceutical Services 2023 annual EBITDA was $0.813B, a 4.83% decline from 2022.
|
West Pharmaceutical Services Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $756 |
| 2024 | $725 |
| 2023 | $813 |
| 2022 | $855 |
| 2021 | $875 |
| 2020 | $516 |
| 2019 | $400 |
| 2018 | $345 |
| 2017 | $323 |
| 2016 | $286 |
| 2015 | $219 |
| 2014 | $272 |
| 2013 | $248 |
| 2012 | $212 |
| 2011 | $185 |
|
West Pharmaceutical Services Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $225 |
| 2026-03-31 | $222 |
| 2025-12-31 | $204 |
| 2025-09-30 | $211 |
| 2025-06-30 | $195 |
| 2025-03-31 | $147 |
| 2024-12-31 | $200 |
| 2024-09-30 | $202 |
| 2024-06-30 | $165 |
| 2024-03-31 | $158 |
| 2023-12-31 | $197 |
| 2023-09-30 | $213 |
| 2023-06-30 | $217 |
| 2023-03-31 | $187 |
| 2022-12-31 | $161 |
| 2022-09-30 | $216 |
| 2022-06-30 | $259 |
| 2022-03-31 | $219 |
| 2021-12-31 | $218 |
| 2021-09-30 | $211 |
| 2021-06-30 | $240 |
| 2021-03-31 | $205 |
| 2020-12-31 | $145 |
| 2020-09-30 | $128 |
| 2020-06-30 | $130 |
| 2020-03-31 | $114 |
| 2019-12-31 | $104 |
| 2019-09-30 | $93 |
| 2019-06-30 | $107 |
| 2019-03-31 | $96 |
| 2018-12-31 | $92 |
| 2018-09-30 | $87 |
| 2018-06-30 | $86 |
| 2018-03-31 | $80 |
| 2017-12-31 | $85 |
| 2017-09-30 | $88 |
| 2017-06-30 | $66 |
| 2017-03-31 | $84 |
| 2016-12-31 | $76 |
| 2016-09-30 | $74 |
| 2016-06-30 | $84 |
| 2016-03-31 | $52 |
| 2015-12-31 | $69 |
| 2015-09-30 | $19 |
| 2015-06-30 | $61 |
| 2015-03-31 | $70 |
| 2014-12-31 | $67 |
| 2014-09-30 | $67 |
| 2014-06-30 | $77 |
| 2014-03-31 | $61 |
| 2013-12-31 | $59 |
| 2013-09-30 | $62 |
| 2013-06-30 | $63 |
| 2013-03-31 | $64 |
| 2012-12-31 | $52 |
| 2012-09-30 | $46 |
| 2012-06-30 | $54 |
| 2012-03-31 | $60 |
| 2011-12-31 | $45 |
| 2011-09-30 | $45 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $25.687B | $3.074B |
| West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments: Proprietary Products and Contract-Manufactured Products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $104.880B | 22.04 |
| Cardinal Health (CAH) | United States | $54.109B | 20.66 |
| Becton Dickinson (BDX) | United States | $51.228B | 14.30 |
| Straumann Holding AG (SAUHY) | Switzerland | $18.592B | 0.00 |
| Align Technology (ALGN) | United States | $10.528B | 16.28 |
| Cooper (COO) | United States | $10.130B | 11.56 |
| Henry Schein (HSIC) | United States | $9.754B | 16.48 |
| Merit Medical Systems (MMSI) | United States | $5.146B | 23.48 |
| DENTSPLY SIRONA (XRAY) | United States | $1.960B | 6.87 |
| CONMED (CNMD) | United States | $1.406B | 9.82 |
| STAAR Surgical (STAA) | United States | $1.125B | 35.07 |
| Pro-Dex (PDEX) | United States | $0.214B | 19.97 |
| Lifevantage (LFVN) | United States | $0.077B | 11.04 |